Objective: Cetuximab-induced skin toxicity has been proposed as a predictive biomarker of treatment efficacy in cetuximab-based regimens. However, its prognostic significance in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) treated with the EXTREME regimen remains limited. This study investi...
M. Fidan, S. Safarov, H. Abbasov et al.· Cerrahpasa Medical Journal· 0 citations
Background: Pathological complete response (pCR) following neoadjuvant systemic therapy (NST) is associated with improved outcomes in breast cancer. We evaluated the association between PET/CT-derived metabolic parameters and pCR and explored whether these associations differed according to molecular subtype. Methods:...
Z. Birsin, Mehmet Taner Bodur, S. Cebeci et al.· Diagnostics· 0 citations
In patients with HR+/HER2− metastatic breast cancer, the site of first progression after CDK4/6 inhibitor therapy may help estimate subsequent prognosis, and routinely available imaging findings may add practical value when assessing risk after CDK4/6 inhibitor failure.
Vali Aliyev, Z. Birsin, M. Günaltılı et al.· Cerrahpasa Medical Journal· 0 citations